9999 Search Results


  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 95
    Cell Signaling Technology Inc iva b
    Demographic differences between participants based on high versus expected in vivo TFV release rates.
    Iva B, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/iva b/product/Cell Signaling Technology Inc
    Average 95 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    iva b - by Bioz Stars, 2023-02
    95/100 stars
      Buy from Supplier

    95
    ATCC b brevis atcc 9999
    Demographic differences between participants based on high versus expected in vivo TFV release rates.
    B Brevis Atcc 9999, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/b brevis atcc 9999/product/ATCC
    Average 95 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    b brevis atcc 9999 - by Bioz Stars, 2023-02
    95/100 stars
      Buy from Supplier

    86
    Medison Pharma Ltd 9999
    Demographic differences between participants based on high versus expected in vivo TFV release rates.
    9999, supplied by Medison Pharma Ltd, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/9999/product/Medison Pharma Ltd
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    9999 - by Bioz Stars, 2023-02
    86/100 stars
      Buy from Supplier

    86
    Millipore c 9999
    Demographic differences between participants based on high versus expected in vivo TFV release rates.
    C 9999, supplied by Millipore, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/c 9999/product/Millipore
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    c 9999 - by Bioz Stars, 2023-02
    86/100 stars
      Buy from Supplier

    86
    Santa Cruz Biotechnology 9999
    Demographic differences between participants based on high versus expected in vivo TFV release rates.
    9999, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/9999/product/Santa Cruz Biotechnology
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    9999 - by Bioz Stars, 2023-02
    86/100 stars
      Buy from Supplier

    Image Search Results


    Demographic differences between participants based on high versus expected in vivo TFV release rates.

    Journal: Frontiers in Cellular and Infection Microbiology

    Article Title: Vaginal Microbiota and Mucosal Pharmacokinetics of Tenofovir in Healthy Women Using a 90-Day Tenofovir/Levonorgestrel Vaginal Ring

    doi: 10.3389/fcimb.2022.799501

    Figure Lengend Snippet: Demographic differences between participants based on high versus expected in vivo TFV release rates.

    Article Snippet: Our PD modeling data also support that the TFV VF concentrations achieved provided significant increases in median HIV-1 inhibition, for women with either LbD CSTs (96% and 97%, at months 1 and 3, respectively) or CST IVA/B (99% and 74% at months 1 and 3, respectively) vaginal microbiota over the median baseline (14% and 4% for LbD and CSTIV, respectively), pre-insertion HIV-1 inhibition levels.

    Techniques: In Vivo, Standard Deviation

    Vaginal fluid TFV concentrations (ng/mg) and vaginal tissue TFV (ng/mg) and TFV-DP (fmol/mg) concentrations among TFV/LNG IVR users (cyclic and continuous cohorts combined) with either Lactobacillus dominated (LbD) or CST IVA/B  microbiota.

    Journal: Frontiers in Cellular and Infection Microbiology

    Article Title: Vaginal Microbiota and Mucosal Pharmacokinetics of Tenofovir in Healthy Women Using a 90-Day Tenofovir/Levonorgestrel Vaginal Ring

    doi: 10.3389/fcimb.2022.799501

    Figure Lengend Snippet: Vaginal fluid TFV concentrations (ng/mg) and vaginal tissue TFV (ng/mg) and TFV-DP (fmol/mg) concentrations among TFV/LNG IVR users (cyclic and continuous cohorts combined) with either Lactobacillus dominated (LbD) or CST IVA/B microbiota.

    Article Snippet: Our PD modeling data also support that the TFV VF concentrations achieved provided significant increases in median HIV-1 inhibition, for women with either LbD CSTs (96% and 97%, at months 1 and 3, respectively) or CST IVA/B (99% and 74% at months 1 and 3, respectively) vaginal microbiota over the median baseline (14% and 4% for LbD and CSTIV, respectively), pre-insertion HIV-1 inhibition levels.

    Techniques:

    (A–C) Correlation of tenofovir (TFV) vaginal fluid concentration with the relative abundance of Gardnerella vaginalis at months 1, 2, and 3. Green dots represent participants who had Lactobacillus-dominated (LbD) vaginal microbiota at the time of sampling and their individual TFV vaginal fluid concentration and relative abundance of Gardnerella vaginalis . Blue dots represent participants who had diverse anaerobe-dominated (CST IVA/B) vaginal microbiota at the time of sampling and their individual TFV vaginal fluid concentration and relative abundance of Gardnerella vaginalis .

    Journal: Frontiers in Cellular and Infection Microbiology

    Article Title: Vaginal Microbiota and Mucosal Pharmacokinetics of Tenofovir in Healthy Women Using a 90-Day Tenofovir/Levonorgestrel Vaginal Ring

    doi: 10.3389/fcimb.2022.799501

    Figure Lengend Snippet: (A–C) Correlation of tenofovir (TFV) vaginal fluid concentration with the relative abundance of Gardnerella vaginalis at months 1, 2, and 3. Green dots represent participants who had Lactobacillus-dominated (LbD) vaginal microbiota at the time of sampling and their individual TFV vaginal fluid concentration and relative abundance of Gardnerella vaginalis . Blue dots represent participants who had diverse anaerobe-dominated (CST IVA/B) vaginal microbiota at the time of sampling and their individual TFV vaginal fluid concentration and relative abundance of Gardnerella vaginalis .

    Article Snippet: Our PD modeling data also support that the TFV VF concentrations achieved provided significant increases in median HIV-1 inhibition, for women with either LbD CSTs (96% and 97%, at months 1 and 3, respectively) or CST IVA/B (99% and 74% at months 1 and 3, respectively) vaginal microbiota over the median baseline (14% and 4% for LbD and CSTIV, respectively), pre-insertion HIV-1 inhibition levels.

    Techniques: Concentration Assay, Sampling

    (A–C) Correlation of tenofovir (TFV) vaginal fluid concentration with the relative abundance of Prevotella species at months 1, 2, and 3. Green dots represent participants who had Lactobacillus-dominated (LbD) vaginal microbiota at the time of sampling and their individual TFV vaginal fluid concentration and relative abundance of Prevotella species. Blue dots represent participants who had diverse anaerobe dominated (CST IVA/B) vaginal microbiota at the time of sampling and their individual TFV vaginal fluid concentration and relative abundance of Prevotella species.

    Journal: Frontiers in Cellular and Infection Microbiology

    Article Title: Vaginal Microbiota and Mucosal Pharmacokinetics of Tenofovir in Healthy Women Using a 90-Day Tenofovir/Levonorgestrel Vaginal Ring

    doi: 10.3389/fcimb.2022.799501

    Figure Lengend Snippet: (A–C) Correlation of tenofovir (TFV) vaginal fluid concentration with the relative abundance of Prevotella species at months 1, 2, and 3. Green dots represent participants who had Lactobacillus-dominated (LbD) vaginal microbiota at the time of sampling and their individual TFV vaginal fluid concentration and relative abundance of Prevotella species. Blue dots represent participants who had diverse anaerobe dominated (CST IVA/B) vaginal microbiota at the time of sampling and their individual TFV vaginal fluid concentration and relative abundance of Prevotella species.

    Article Snippet: Our PD modeling data also support that the TFV VF concentrations achieved provided significant increases in median HIV-1 inhibition, for women with either LbD CSTs (96% and 97%, at months 1 and 3, respectively) or CST IVA/B (99% and 74% at months 1 and 3, respectively) vaginal microbiota over the median baseline (14% and 4% for LbD and CSTIV, respectively), pre-insertion HIV-1 inhibition levels.

    Techniques: Concentration Assay, Sampling

    (A–D) Correlation of TFV (A) and TFV-DP (C) tissue concentrations with relative abundance of G. vaginalis species and fit of the linear model with CST IV samples at the end of treatment with TFV tissue concentrations (B) and TFV-DP tissue concentrations (D) . Green dots represent participants who had Lactobacillus-dominated (LbD) vaginal microbiota at the time of sampling and their individual TFV vaginal fluid concentration and relative abundance of Gardnerella vaginalis . Blue dots represent participants who had diverse anaerobe-dominated (CST IVA/B) vaginal microbiota at the time of sampling and their individual TFV vaginal fluid concentration and relative abundance of Gardnerella vaginalis . Black dots in the linear fit model represent participants who had diverse anaerobe-dominated (CST IVA/B) vaginal microbiota at the time of sampling and their individual TFV vaginal fluid concentration and relative abundance of Gardnerella vaginalis .

    Journal: Frontiers in Cellular and Infection Microbiology

    Article Title: Vaginal Microbiota and Mucosal Pharmacokinetics of Tenofovir in Healthy Women Using a 90-Day Tenofovir/Levonorgestrel Vaginal Ring

    doi: 10.3389/fcimb.2022.799501

    Figure Lengend Snippet: (A–D) Correlation of TFV (A) and TFV-DP (C) tissue concentrations with relative abundance of G. vaginalis species and fit of the linear model with CST IV samples at the end of treatment with TFV tissue concentrations (B) and TFV-DP tissue concentrations (D) . Green dots represent participants who had Lactobacillus-dominated (LbD) vaginal microbiota at the time of sampling and their individual TFV vaginal fluid concentration and relative abundance of Gardnerella vaginalis . Blue dots represent participants who had diverse anaerobe-dominated (CST IVA/B) vaginal microbiota at the time of sampling and their individual TFV vaginal fluid concentration and relative abundance of Gardnerella vaginalis . Black dots in the linear fit model represent participants who had diverse anaerobe-dominated (CST IVA/B) vaginal microbiota at the time of sampling and their individual TFV vaginal fluid concentration and relative abundance of Gardnerella vaginalis .

    Article Snippet: Our PD modeling data also support that the TFV VF concentrations achieved provided significant increases in median HIV-1 inhibition, for women with either LbD CSTs (96% and 97%, at months 1 and 3, respectively) or CST IVA/B (99% and 74% at months 1 and 3, respectively) vaginal microbiota over the median baseline (14% and 4% for LbD and CSTIV, respectively), pre-insertion HIV-1 inhibition levels.

    Techniques: Sampling, Concentration Assay

    Percent inhibition of HIV in vitro by cervicovaginal fluid lavage (CVL) supernatant obtained from study participants using the TFV/LNG IVR at baseline (BL) pre-insertion, month 1 (M1), and end of treatment month 3 (M3). Red dots represent participant data from individuals with diverse anaerobic CST IVA/B microbiota at sampling. Blue dots represent participant data from individuals with Lactobacillus-dominated (LbD) microbiota at sampling. p values < 0.01 paired change from BL in percent HIV inhibition at months 1 and months 3 for both LbD and CST IVA/B groups.

    Journal: Frontiers in Cellular and Infection Microbiology

    Article Title: Vaginal Microbiota and Mucosal Pharmacokinetics of Tenofovir in Healthy Women Using a 90-Day Tenofovir/Levonorgestrel Vaginal Ring

    doi: 10.3389/fcimb.2022.799501

    Figure Lengend Snippet: Percent inhibition of HIV in vitro by cervicovaginal fluid lavage (CVL) supernatant obtained from study participants using the TFV/LNG IVR at baseline (BL) pre-insertion, month 1 (M1), and end of treatment month 3 (M3). Red dots represent participant data from individuals with diverse anaerobic CST IVA/B microbiota at sampling. Blue dots represent participant data from individuals with Lactobacillus-dominated (LbD) microbiota at sampling. p values < 0.01 paired change from BL in percent HIV inhibition at months 1 and months 3 for both LbD and CST IVA/B groups.

    Article Snippet: Our PD modeling data also support that the TFV VF concentrations achieved provided significant increases in median HIV-1 inhibition, for women with either LbD CSTs (96% and 97%, at months 1 and 3, respectively) or CST IVA/B (99% and 74% at months 1 and 3, respectively) vaginal microbiota over the median baseline (14% and 4% for LbD and CSTIV, respectively), pre-insertion HIV-1 inhibition levels.

    Techniques: Inhibition, In Vitro, Sampling

    Cumulative (CUMU) p24 antigen production from cervicovaginal (CV) tissue biopsies obtained from all participants at baseline and from participants using the placebo IVR (BL). CUMU p24 antigen production from CV tissue biopsies obtained from participants using the TFV/LNG IVR at end of treatment (EOT). Red dots represent participant data from individuals with diverse anaerobic CST IVA/B microbiota at sampling. Blue dots represent participant data from individuals with Lactobacillus-dominated (LbD) microbiota at sampling. p values > 0.05 for change in p24 antigen production from tissues at EOT compared to BL.

    Journal: Frontiers in Cellular and Infection Microbiology

    Article Title: Vaginal Microbiota and Mucosal Pharmacokinetics of Tenofovir in Healthy Women Using a 90-Day Tenofovir/Levonorgestrel Vaginal Ring

    doi: 10.3389/fcimb.2022.799501

    Figure Lengend Snippet: Cumulative (CUMU) p24 antigen production from cervicovaginal (CV) tissue biopsies obtained from all participants at baseline and from participants using the placebo IVR (BL). CUMU p24 antigen production from CV tissue biopsies obtained from participants using the TFV/LNG IVR at end of treatment (EOT). Red dots represent participant data from individuals with diverse anaerobic CST IVA/B microbiota at sampling. Blue dots represent participant data from individuals with Lactobacillus-dominated (LbD) microbiota at sampling. p values > 0.05 for change in p24 antigen production from tissues at EOT compared to BL.

    Article Snippet: Our PD modeling data also support that the TFV VF concentrations achieved provided significant increases in median HIV-1 inhibition, for women with either LbD CSTs (96% and 97%, at months 1 and 3, respectively) or CST IVA/B (99% and 74% at months 1 and 3, respectively) vaginal microbiota over the median baseline (14% and 4% for LbD and CSTIV, respectively), pre-insertion HIV-1 inhibition levels.

    Techniques: Sampling